A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

I8G-MC-LMDD -

This study involves repeated doses of LY3303560 given by injection for 25 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or Alzheimer's Disease, and how LY3303560 is handled by the body and acts in the body.

Trial Summary

Age Range
≥50 years
Conditions the trial is for
Alzheimer's Disease
What the trial is testing?
LY3303560
Could I receive a Placebo?
No
Enrollment Goal
22
Trial Dates
Jan 31, 2017 - Jun 5, 2019
How long will I be in the trial?
participation could last up to 18.5 months and include up to 27 visits to the study center.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.